Novo Nordisk and Eli Lilly are expected to rule the obesity market for a few more years without much challenge. To ensure they stay there as competition enters, the companies are spending billions in ...
Amgen said on Tuesday that its drug helped improve daily activities including chewing and swallowing in patients suffering ...
Sen. Bernie Sanders said on Tuesday he had commitments from the nation's top pharmacy benefit managers that they would expand ...
The government’s antitrust watchdog on Friday sued three massive health conglomerates, accusing their drug middlemen of ...
Eli Lilly & Co. closed $48.10 short of its 52-week high ($972.53), which the company achieved on August 22nd.
Tolerability issues for CT-388 and CT-996 may impact Roche Holdings AG, but strong pipeline prospects remain. Discover why ...
Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for ...
Buying $1000 In LLY: If an investor had bought $1000 of LLY stock 20 years ago, it would be worth $15,297.50 today based on a ...
China has started cracking down on unlicensed production and sale of medicines similar to Novo Nordisk A/S’s blockbuster ...
In a landmark move, the FTC filed a lawsuit targeting the “Big Three” PBMs: CVS Health’s Caremark Rx, Cigna’s Express Scripts (ESI), and UnitedHealth Group’s OptumRx. The suit also includes their ...
Japan, with its rapidly aging population, is expected to have more than 5 million patients with dementia by 2030. Alzheimer’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback